79 Results

People

  1. Usmani
    Usmani
  2. Lesokhin
    Lesokhin
  3. Mailankody
    Mailankody
  4. Korde
    Korde
  5. Giralt
    Giralt
  6. Landau
    Landau
  7. Shah
    Shah
  8. Hassoun
    Hassoun
  9. Landgren
    Landgren
  10. Hultcrantz
    Hultcrantz

Groups

  1. Department of Medicine (45)
  2. Hematologic Malignancies, Division of (44)
  3. Center for Hematologic Malignancies (43)
  4. Myeloma (29)
  5. Hematologic Malignancies Research (21)
  6. Survivorship Research (20)
  7. Bone Marrow Transplant (18)
  8. CTCR Scholars (13)
  9. Graduate Medical Education (11)
  10. Sloan Kettering Institute Postdocs (11)
  1. "daratumumab"
Formats
  1. Journal Article (48)
  2. Review (16)
  3. Research Letter (8)
  4. Meeting Abstract (3)
  5. Editorial (2)
  6. Conference Paper (1)
  7. Correspondence (1)
Groups
  1. Department of Medicine (45)
  2. Hematologic Malignancies, Division of (44)
  3. Center for Hematologic Malignancies (43)
  4. Myeloma (29)
  5. Hematologic Malignancies Research (21)
  6. Survivorship Research (20)

More Groups

People
  1. Saad Usmani (28)
  2. Alexander Lesokhin (15)
  3. Sham Mailankody (14)
  4. Neha Korde (13)
  5. Heather Landau (12)
  6. Sergio Giralt (12)

More People

Years
  1. 2025 (8)
  2. 2024 (23)
  3. 2023 (12)
  4. 2022 (8)
  5. 2021 (7)
  6. 2020 (8)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (7)
  2. American Journal of Hematology (6)
  3. Leukemia (5)
  4. Blood Cancer Journal (4)
  5. Blood (3)
  6. Blood Advances (3)

More Publications

Publishers
  1. Elsevier Inc. (15)
  2. Nature Publishing Group (11)
  3. American Society of Hematology (6)
  4. John Wiley & Sons, Inc. (6)
  5. Elsevier Science, Inc. (5)
  6. Frontiers Media S.A. (5)

More Publishers

Results (79)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes: MULTIPLE MYELOMA, GAMMOPATHIES
    Journal Article

    Facon, T.; Moreau, P.; Weisel, K.; Goldschmidt, H.; Usmani, S. Z.; Chari, A.; Plesner, T.; Orlowski, R. Z.; Bahlis, N.; Basu, S.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of B-cell maturation antigen (BCMA) NEX-T® chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
    Journal Article

    Ravi, G.; Richard, S.; Kumar, S.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes
    Journal Article

    Perrot, A.; Facon, T.; Plesner, T.; Usmani, S. Z.; Kumar, S.; Bahlis, N. J.; Hulin, C.; Orlowski, R. Z.; Nahi, H.; Mollee, P.; more...
    European Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: Analysis of key subgroups of the MAIA study
    Journal Article

    Moreau, P.; Facon, T.; Usmani, S. Z.; Bahlis, N.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • CD38-targeted 89Zr-DFO-daratumumab PET of myeloma: Immuno-PET impacting clinical care
    Editorial

    Ulaner, G. A.; Lewis, J.; Landgren, O.
    Journal of Nuclear Medicine (2025)

    Fulltext@MSK | Save
  • MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Journal Article

    Bhutani, M.; Robinson, M.; Foureau, D.; Atrash, S.; Paul, B.; Guo, F.; Grayson, J. M.; Ivanina-Foureau, A.; Pineda-Roman, M.; Varga, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma
    Review

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
    Journal Article

    Goel, U.; Dima, D.; Davis, J.; Ahmed, N.; Shaikh, H.; Lochner, J.; Abdallah, A. O.; Khouri, J.; Hashmi, H.; Anwer, F.
    European Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: The DELPHINUS study
    Journal Article

    Bhatla, T.; Hogan, L. E.; Teachey, D. T.; Bautista, F.; Moppett, J.; Velasco Puyó, P.; Micalizzi, C.; Rossig, C.; Shukla, N.; Gilad, G.; more...
    Blood (2024)

    Fulltext@MSK | Save